

ISPOR Warsaw 2019 28 March 2019





Ernesto Nogueira
ValueConnected
The Hague, Netherlands



Claudia Wild LBI-HTA Vienna, Austria



Rok Hren University of Ljubljana Ljubljana, Slovenia



**Bence Takács** OGYEI Budapest, Hungary





Ernesto Nogueira, MBA ValueConnected The Hague, Netherlands





Claudia Wild, PhD LBI-HTA Vienna, Austria

# **EUnetHTA**

**European Network for Health Technology Assessment** 

**!! HTA on Medical Devices in Europe:** European Collaboration !!

Claudia Wild, Director LBI-HTA



# Planned and ongoing projects (POP) database

around 900 ongoing projects in Europe (at any time)


POP statistics as of March 2019: 868 projects in 44 agencies (20 countries):

88 topics overlapping (= 10% identical topics, STA):
54 for 2 agencies, 22 for 3 agencies, 9 for 4 agencies and
3 for 5 agencies!

225 similar projects (= 26% same indication, MTA)

# Type of use (medical device HTA)

- Most agencies add additional information
- Compared with pharmaceuticals more agencies are able to use the assessments with either no changes or translation only





Data: February 2019

#### **EUnetHTA** intentions:

- To reduce overlap and duplication of effort and hence
- To promote more effective use of HTA-resources: increase efficiency
- To facilitate good practice in HTA methods and processes (capacity building, methodological consistency, harmonization of reporting)





Claudia Wild, PhD LBI-HTA Vienna, Austria





Rok Hren, PhD, MSc University of Ljubljana Ljubljana, Slovenia

# From oligopoly to monopoly

Tender dossier	Financial part	Technical part
The tender dossier sets out the criteria for the most economically advantageous offer on the basis of scoring - a total of 100 points.	Price offered for a system - <b>60 points</b> , defined by the equation: (the lowest bidding price) / (price of the provider) * 60	Four technical categories of the system - up to 40 points

		Financial					Technical specification -	
	System	part - points	1	2	3	4	total	Total points
Provider R	485.000	42,06	8	6	6	20	40	82,06
Provider J	380.000	53,68	4	6	4	14	28	81,68
Provider G	350.000	58,29	2	6	2	12	22	80,29
Provider P	340.000	60,00	0	4	4	14	22	82,00

### From costs of tests to costs of diagnostics

Monitoring HbA1c	Germany	Belgium	Switzerland
LD HbA1c test cost	0.5€	1 €	1€
LD test follow-up cost	5€	5€	10 €
POC HbA1c test cost	3.5€	4.5€	4€
POC test follow-up cost	0 €	0€	0€





Rok Hren, PhD, MSc University of Ljubljana Ljubljana, Slovenia






Bence Takács OGYEI Budapest, Hungary

# Medical Aids (Class I-IIb) Reimbursement Procedure


#### Important to note:

- We are critically appraising manufacturer submissions (no self-initiated procedures)
- The department issues
   advisory documents, the
   decision is made at
   ministerial/NHIF level





# Other Technologies (Class III) Reimbursement Procedure









Bence Takács OGYEI Budapest, Hungary





Ernesto Nogueira
ValueConnected
The Hague, Netherlands



Claudia Wild LBI-HTA Vienna, Austria



Rok Hren University of Ljubljana Ljubljana, Slovenia



**Bence Takács** OGYEI Budapest, Hungary